Nektar's new pathways to smarter medicine bring hope to millions of patients by creating innovative medicines that treat serious & widespread unmet medical needs.

Feb 24, 2025 · Nektar's lead product candidate, rezpegaldesleukin is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata.

Medicines for which licenses have been granted to third-parties in the United States; also, information on U.S. medicines using Nektar technologies.

Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of autoimmune disorders, chronic inflammatory conditions and cancer.

Dec 31, 2024 · SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023 .

Mar 20, 2025 · Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata.

Not currently logged in Sign In. Home

SUPPORT PORTAL English (US) Representatives

Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders.

Nektar Therapeutics. 455 Mission Bay Boulevard South. San Francisco, California 94158 (415) 482-5300 (Name , addre s s , i nc l udi ng z i p c ode , and te l e phone numbe r, i nc l udi ng are a c ode , of age nt for s e r vi c e ) Copy to: Sam Zucker. Justin Platt. Goodwin Procter LLP. 601 Marshall Street. Redwood City, CA 94063 (650) 752-3100